In silico repositioning of approved drugs for rare and neglected diseases

S Ekins, AJ Williams, MD Krasowski, JS Freundlich - Drug discovery today, 2011 - Elsevier
One approach to speed up drug discovery is to examine new uses for existing approved
drugs, so-called 'drug repositioning'or 'drug repurposing', which has become increasingly …

Potential repurposed drug candidates for tuberculosis treatment: progress and update of drugs identified in over a decade

K Sharma, F Ahmed, T Sharma, A Grover… - ACS …, 2023 - ACS Publications
The devastating impact of Tuberculosis (TB) has been a menace to mankind for decades.
The World Health Organization (WHO) End TB Strategy aims to reduce TB mortality up to …

Doxycycline host-directed therapy in human pulmonary tuberculosis

QH Miow, AF Vallejo, Y Wang, JM Hong… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND Matrix metalloproteinases (MMPs) are key regulators of tissue destruction in
tuberculosis (TB) and may be targets for host-directed therapy. We conducted a phase II …

Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases

NF Walker, SO Clark, T Oni, N Andreu… - American journal of …, 2012 - atsjournals.org
Rationale: Tuberculosis kills more than 1.5 million people per year, and standard treatment
has remained unchanged for more than 30 years. Tuberculosis (TB) drives matrix …

Synthesis, structure–activity relationship of novel substituted 4H-chromen-1, 2, 3, 4-tetrahydropyrimidine-5-carboxylates as potential anti-mycobacterial and anticancer …

BC Raju, RN Rao, P Suman, P Yogeeswari… - Bioorganic & Medicinal …, 2011 - Elsevier
Abstract Series of 4H-chromen-1, 2, 3, 4-tetrahydropyrimidine-5-carboxylate derivatives 7a–
7zb, 8a–8d and 9a–9d were synthesized and screened for their in vitro anti-mycobacterial …

Antibacterial activity of long-chain fatty alcohols against mycobacteria

K Mukherjee, P Tribedi… - FEMS microbiology …, 2013 - academic.oup.com
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and results in
innumerable deaths across the world. The emergence of multidrug-resistant and extremely …

Antimicrobial peptides as an alternative to anti-tuberculosis drugs

M AlMatar, EA Makky, G Yakıcı, I Var, B Kayar… - Pharmacological …, 2018 - Elsevier
Tuberculosis (TB) presently accounts for high global mortality and morbidity rates, despite
the introduction four decades ago of the affordable and efficient four-drugs (isoniazid …

Looking beyond typical treatments for atypical mycobacteria

CM Bento, MS Gomes, T Silva - Antibiotics, 2020 - mdpi.com
The genus Mycobacterium comprises not only the deadliest of bacterial pathogens,
Mycobacterium tuberculosis, but several other pathogenic species, including M. avium and …

[HTML][HTML] Repurposing—a ray of hope in tackling extensively drug resistance in tuberculosis

A Maitra, S Bates, T Kolvekar, PV Devarajan… - International Journal of …, 2015 - Elsevier
Tuberculosis (TB) remains a serious concern more than two decades on from when the
World Health Organization declared it a global health emergency. The alarming rise of …

Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold

M Krátký, J Vinšová, M Volková, V Buchta… - European journal of …, 2012 - Elsevier
A series of novel sulfonamides containing 5-chloro-2-hydroxybenzaldehyde or 5-chloro-2-
hydroxybenzoic acid scaffolds were designed, synthesized and characterized by IR, 1H …